

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
Infectious disease	Complement 3 (C3)	<p>Two separate <i>in vitro</i> studies resolved the crystal structures of C3 components that could be targeted to help treat infection. The crystal structure of the transient C3 convertase and the crystal structure of the interaction between complement factor H with C3b, a component of C3, were both resolved to suggest possible site targets. Next steps could include using the information to develop therapeutics directed at modulating complement activation.</p> <p><b>SciBX 2(26); doi:10.1038/scibx.2009.1051</b>  <b>Published online July 9, 2009</b></p>	Patent and licensing status unavailable	<p>Rooijackers, S. <i>et al. Nat. Immunol.</i>; published online June 7, 2009; doi:10.1038/ni.1756  <b>Contact:</b> John Lambris, University of Pennsylvania, Philadelphia, Pa.            e-mail:  <a href="mailto:lambris@mail.med.upenn.edu">lambris@mail.med.upenn.edu</a></p> <p>Wu, J. <i>et al. Nat. Immunol.</i>; published online June 7, 2009; doi:10.1038/ni.1755  <b>Contact:</b> Piet Gros, Utrecht University, the Netherlands            e-mail:  <a href="mailto:p.gros@uu.nl">p.gros@uu.nl</a></p>